TreatSMA attends Cambridge Rare Disease Network summit

TreatSMA were fortunate enough to be invited to the event along with having a stand for people to come and talk to us about our journey fighting for treatments for rare diseases.

The event was held at the world-famous Wellcome genome campus in Cambridge and had a huge number of speakers from industry, scientific and patient arenas. Talks arranged from looking back at 25 years of rare disease treatment development, talking about recent successes (SMA was mentioned), as well as how the process can change going forward. There were lots of panel discussions around patient involvement and how technology has a huge role to play in the future.

Baroness Nicola Blackwood also attended the event and gave a short talk focusing on what matters most to patients and also looking at what priorities should be set in the upcoming 2020 strategy framework for UK Rare Disease.

It was an enlightening event and hopefully provided research organisations and Baroness Blackwood food for thought.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more